Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib-Reference-Cited by-同舟云学术

Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib

Published:2016-02-22 Issue:11 Volume:46 Page:967-976
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Nishiya Yumi¹,Nakai Daisuke¹,Urasaki Yoko¹,Takakusa Hideo¹,Ohsuki Satoru²,Iwano Yuji²,Yasukochi Takanori²,Takayama Tomoko³,Bazyo Shohei³,Oza Chikahiro³,Kurihara Atsushi¹,Savage Ronald E⁴,Izumi Takashi⁵

Affiliation:

1. Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan,

2. Organic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan,

3. Discovery Science and Technology Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan,

4. ArQule, Inc., Woburn, MA, USA, and

5. Research Function, Daiichi Sankyo Co., Ltd., Tokyo, Japan

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3109/00498254.2016.1144896

Reference25 articles.

1. Early Clinical Development of ARQ 197, a Selective, Non–ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

2. Retinoids, ω-hydroxyfatty acids and cytotoxic aldehydes as physiological substrates, and H2-receptor antagonists as pharmacological inhibitors, of human class IV alcohol dehydrogenase

3. Gender Differences in Pharmacokinetics of Alcohol

4. Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ADH4—a potential prognostic marker for hepatocellular carcinoma with possible immune-related implications;BMC Cancer;2024-08-01

2. ADH4—a potential prognostic marker for hepatocellular carcinoma with possible immune-related implications;2024-04-19

3. Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development;Annual Review of Pharmacology and Toxicology;2022-01-06

4. Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity;Pharmacology & Therapeutics;2021-10

5. Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors;Cancer Chemotherapy and Pharmacology;2021-06-23